#Hydroxychloroquine Tablet Exporter

[tritonmarketresearchamey]

India's Pharmaceutical Market: Key Trends & Drivers Explained

The Indian pharmaceutical industry is set for remarkable growth, expected to reach $65 billion by 2024 and $130 billion by 2030, up from its current $50 billion valuation, according to Invest India. As a leading exporter, India serves over 200 countries, supplying more than 50% of Africa’s generic drugs, about 40% of the United States’ generic drug demand, and 25% of the UK’s medicines. India also accounts for around 60% of global vaccine demand and provides 70% of the World Health Organization’s essential immunization vaccines, including DPT, BCG, and Measles. This expansion highlights India’s crucial role in the global healthcare sector, highlighting its robust export capabilities and significant contributions to vaccine supply.

India’s Rising Importance in The Global Pharmaceutical Landscape

India’s pharmaceutical industry sees exports accounting for over $25 billion, supplying 20% of global generic medicines demand. This growth positions India with about 13% of the global pharmaceutical market share. Also, according to the Indian Brand Equity Foundation (IBEF), the nation is the third-largest producer of active pharmaceutical ingredients (APIs), holding 8% of the global market share and manufacturing over 500 APIs.

According to the Department of Pharmaceuticals, Indian pharmaceutical firms are key players in the United States and European Union (EU) prescription drug sectors, with the highest number of FDA-approved manufacturing plants outside the US. As the world’s largest supplier of generic medicines, the nation meets 20% of global demand by volume. Globally valued at $42 billion, India’s pharmaceutical industry saw nearly 5% year-on-year growth in FY23, reaching $49.78 billion. This growth, driven by an 8% increase in exports and a 6% rise in domestic market growth from FY18 to FY23, underscores India’s role as a major pharmaceutical hub.

The sector further ranks among India’s top ten industries attracting foreign investment, with exports reaching highly regulated markets like the US, Western Europe, Japan, and Australia. During the global health crisis, India demonstrated its capability by supplying around 45 tons and 400 million hydroxychloroquine tablets to 114 countries.

Driving Forces in India’s Pharmaceutical Market

India’s pharmaceutical industry is driven by population growth, urbanization, and an increasing prevalence of chronic diseases. Rising healthcare expenditures, supported by both public and private sectors, further boost the industry growth. In this regard, government initiatives like ‘Ayushman Bharat Yojana’ significantly enhance medication accessibility.

Additionally, schemes like the Production Linked Incentive (PLI) scheme promote domestic manufacturing to reduce import dependency, while the Development of Pharmaceutical Industry (DPI) scheme enhances efficiency and competitiveness through sub-schemes for Bulk Drugs and Medical Devices. These efforts aim to elevate India’s global pharma presence and provide affordable, quality healthcare solutions. Increased investments in research and development (R&D) for new drugs further reinforce India’s significant role in global pharmaceutical innovation.

Major companies, such as Sun Pharma and Mankind, are expanding their market reach by deploying 12,000 medical representatives in urban and rural areas to engage with healthcare professionals.

Regulatory Environment & Advancing Tech in The Indian Pharmaceutical Industry

The pharmaceutical industry in India operates under stringent regulatory oversight to ensure drug safety, efficacy, and quality. The Central Drugs Standard Control Organization (CDSCO) , under the Ministry of Health & Family Welfare, controls the manufacture, import, distribution, and drug sales through the Drugs & Cosmetics Act 1940. The Drugs and Magic Remedies (Objectionable Advertisement) Act 1954 regulates drug advertising, prohibiting claims of miraculous properties.

Further, Good Clinical Practice (GCP) guidelines, developed in collaboration with the Drugs Controller General of India (DCGI) and the Indian Council for Medical Research (ICMR) , set standards for human subject research aligning with international norms like the Declaration of Helsinki and World Health Organization (WHO) guidelines. Its regulatory framework also aligns with international guidelines, including the International Conference on Harmonization (ICH) standards and regulations from bodies like the US FDA and the European Medicines Agency (EMA) , ensuring compliance with global standards.

In recent years, the Indian pharmaceutical sector has been at the forefront of technological innovation, harnessing artificial intelligence (AI), big data analytics, telemedicine, and the Internet of Medical Things (IoMT) to revolutionize healthcare delivery. PharmEasy, launched in 2015, stands as a prime example that has democratized healthcare access by seamlessly connecting patients with nearby pharmacies and diagnostic centers. Similarly, Cipla is digitizing its pharmaceutical sales approach by equipping medical representatives with iPads for e-detailing. This digital transformation enhances sales effectiveness via streamlined communication and interactive engagement with healthcare providers. This wave of innovation is supported by initiatives like the Scheme for Promotion of Research and Innovation in the Pharma MedTech Sector (PRIP) , launched in 2023.

Global Interest Supports the Indian Pharma Sector

The Indian pharmaceutical sector attracts significant foreign direct investment (FDI) due to liberalized policies, allowing up to 100% FDI for Greenfield projects and up to 74% for Brownfield ventures. Since April 2000, the sector has drawn around $22.52 billion in FDI equity inflows, supported by over 10,000 Pradhan Mantri Bhartiya Janaushadhi Kendras nationwide. Major global players such as AstraZeneca, Dr. Reddy’s, and Pfizer have heavily invested in India’s pharmaceutical industry, leveraging its manufacturing and regulatory strengths.

Hence, this sector is set for significant growth in the next decade, driven by its role in global trade and compliance with GMP standards from WHO and USFDA. As a leading producer of generics, India expects around 912% increase in medicine spending over the next five years, placing it among the top global markets. Growth will focus on chronic therapies like cardiovascular and anti-cancer treatments. Besides, pharma companies will adopt FMCG-like strategies, manage diverse channels, and leverage the influence of pharmacists and patient empowerment. Government initiatives and expanding access to low-cost generics will further support this growth.

[rohans18]

Hydroxychloroquine Market Growth, Segments, Demand and Forecast to 2030

Global Hydroxychloroquine Market, By Strength (200 mg, 400 mg, 800 mg), Drug Class (Antimalarial, Anti-rheumatic Hydroxychloroquine Drug, Lupus Suppressant Hydroxychloroquine Drug, Hydroxychloroquine Drug, Anti-COVID 19 Hydroxychloroquine Drug), Grade (USP Standards Grade, EP Standards Grade, Pharmaceutical Standards Grade, Others), Dosage Forms (Tablets, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.

In the consistent Hydroxychloroquine market research report, industry trends are put together on macro level with which clients can figure out market landscape and possible future issues about Hydroxychloroquine industry. The scope of this market report include but is not limited to latest trends, market segmentation, new market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target market analysis, insights and innovation. The report presents with the CAGR value fluctuations for the specific forecasted period which helps decide costing and investment strategies. An influential Hydroxychloroquine market report brings precise and exact market research information that drives business into the right direction.

Key Players

bioMérieux (France)

Merck KGaA (Germany)

RayBiotech Life Inc. (U.S.)

R&D Systems, Inc. (U.S.)

GROUP GmbH & Co. KG (Germany)

Eurofins Scientific (Luxembourg)

Biogenuix (India)

Hoffmann-La Roche Ltd (Switzerland)

Abbott (U.S.)

Danaher (U.S.)

Sysmex Corporation (Japan)

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-hydroxychloroquine-market   

The research studies entailed in the winning Hydroxychloroquine market report supports to estimate several important aspects that includes but are not limited to investment in a rising market, success of a new product, and expansion of market share. The strategies underlined here mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that boost footprints in this market. Several other factors such as import, export, gross margin, price, cost, and consumption are also analyzed under the section of production, supply, sales and market status.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Hydroxychloroquine Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

[news-fyi]

India exports 50 million hydroxychloroquine tablets to U.S. for COVID-19 fight: source https://bit.ly/2SoygHg

[davesdiary83]

Anti-Vaccine Campaigns; How Dangerous?

Since its origin in 1796, Vaccines are widely opposed by some despite of its great contributions towards eradication of contagious or other deadly diseases.

The smallpox vaccine was the first vaccine to be developed against a contagious disease. In 1796, the British doctor Edward Jenner demonstrated that an infection with the relatively mild cowpox virus conferred immunity against the deadly smallpox virus. Cowpox served as a natural vaccine until the modern smallpox vaccine emerged in the 19th century. The term vaccine derives from the Latin word for cow, reflecting the origins of smallpox vaccination.

Amongst the vaccine haters, there were literates, illiterates and even some medical practitioners. The reasons for the oppose are sometimes religious or lack of sterilized procedures, otherwise pure business or political. However, modern education has provided notable contribution in changing the mentality of common man favorable to Vaccines.

But, in this modern era too, there are some people who thinks that Vaccine is nothing but business. Agreeing the fact that there are some business in the Vaccine production like any other medicine in the world, denial of the same would be dangerous not only to the individual, but also to the society.

WHO quotes a recent study from the Indian State of Kerala (most literate state in India which is close to 100%) reported by Indian Medical Association (IMA) who are their counter partner in the Country. In one of the district, some people started a campaign against routine Vaccines for kids in the name of religious and traditional reasons. As a result, in the year of 2019, around 50 diphtheria cases were reported (first after some 30 years) among many were passed away. The district and state medical authorities had taken strict action against this and some of the “hate speakers” were put behind the bars.

In this very critical hour of Covid-19 spread also, there are some people who think against Vaccines. Dr. Stephen Karanja who was the chairman of Kenya Catholic Doctors Association, was the strongest face of those haters in Kenya. He advocated steam inhalation and hydroxychloroquine tablets and preached against the safety of Covid Jabs which in turn was rejected by the WHO. "[The vaccine] being distributed in Kenya, has been reviewed and found safe not only by the WHO rigorous process but also by several stringent regulatory authorities," the WHO said in March.

Now, a very sad news has come out that Dr. Karanja has passed away due to Covid-19.

Kenya, just like other African developing countries, has received just over a million vaccine doses from the global Covax initiative, most of which have been administered. The country has confirmed more than 160,000 cases and 2,707 deaths. In March, the government imposed another lockdown restricting movement in five counties after a surge in new infections. They were planning to have dosages from India where the worst wave is hitting (around 400,000 cases and 4,000 deaths per day) which is very unlikely considering the present situations.

Meanwhile, Kenya is having some dosages of Sputnik Vaccines, but were ordered to re-export, which is believed to be due to some political games. Hope the Authorities will open their eyes soon and take appropriate and wise decisions rather than carried away with political egos.

[brajeshupadhyay]

New Delhi: The first shipment of medical equipment, carrying 5.5 million tablets of hydroxychloroquine - an anti-malarial drug identified by the US Food and Drug Administration as a possible treatment for the COVID-19 - is currently on its way to the United Arab Emirates (UAE) from India and will reach its destination soon. "Under guidance of UAE leadership, @UAEembassyIndia succeeded in obtaining the approval of the Indian government to export adequate quantities of #Hydroxychloroquine to UAE," the Emirates' Mission in New Delhi said on its Twitter page. "The first shipment of medicine, currently on its way to the #UAE, includes 5.5 million pills for treatment of patients with #Covid_19. We highly appreciate the cooperation of the Indian government in facilitating the procedures for obtaining the necessary approvals," it said further. India, the major producer of hydroxychloroquine, has promised to supply the drug to 55 countries, including Bhutan, Bangladesh, Maldives, Sri Lanka, and Myanmar as well. The medication which is being used in COVID-19 therapy has already reached the United States, Afghanistan, Mauritius, Kazakhstan, Brazil, and Seychelles. Another consignment of hydroxychloroquine is also on the way to Nepal. Earlier this month, the Ministry of Health and Family Welfare had said that the government has more than enough stock of HCQ for meeting the current requirement. It had said that the Centre has done proper preparation and planning with respect to current and future requirements of the drug.

http://sansaartimes.blogspot.com/2020/04/india-sends-first-shipment-of-55.html

[healthwellonline]

(via Hydroxychloroquine Tablets for Coronavirus, Health Benefits for Malaria, Uses, Side Effects, Interactions, Price in India)

No country in the world has succeeded in making medicines to prevent corona infection. Meanwhile, the drug used in the treatment of malaria is hydroxychloroquine once again in discussion. Donald Trump said that India could retaliate if it did not lift the ban on exports of hydroxychloroquine.

[dayas125-blog]

Best Medicine for COVID-19 is Hydroxychloroquine

Hydroxychloroquine and the related Drug Chloroquine are currently studying possible treatments for COVID-19. This is a disease caused by the new Corona. These drugs have not been approved by the FDA for this purpose. Do not use this drug to treat COVID-19 unless your doctor advises you to do so.

India is the world's largest producer of Hydroxychloroquine (HCQ), which produces $51 million worth of drugs. This is only a fraction of the country's $19 0 million in drug exports.

 The center itself acquired 100,000 IPCA Labs. Producers claim that the Indian market has enough share stake to make a surplus possible. They are going to provide services to the government by this month. In addition, China does not produce HCQ, and India is the world's largest supplier, they added.

 HCQ and Chloroquine Phosphate sit in the same class of drugs. Chloroquine is an antimalarial agent used to prevent and treat malaria.

 HCQ, on the other hand, is used to treat autoimmune diseases such as rheumatoid arthritis, lupus, and as a third-line treatment for diabetes.

 Some health researchers use a combination of HCQ, as well as the common antibiotic azithromycin, as a possible treatment for Covid-19. In a government report, India recommended the use of HCQ for medical personnel and high-risk populations to prevent infection.

 The drug is also given to patients in The Cavid-19. However, experts should caution against the widespread use of the drug until clinical trials have proven beyond any doubt. At the news conference on 19 March, the FDA said that it worked with other governmental and academic centers to investigate the use of chloroquine to determine if it could be used for treatment.

 Healing Pharma Provide You Hydroxychloroquine Sulphate Tablets USP for Cure for Corona Virus Symptoms.  For More Information You can mail on sales@healinpharma.in.

Courtesy: https://www.healingpharma.in/2020/04/08/best-medicine-for-covid-19-is-hydroxychloroquine/

[swarajya7793]

Significant Impact of COVID-19 on Favipiravir in Pharmaceutical Industry

COVID-19 Impact on Favipiravir in Pharmaceutical Industry

OVERVIEW

A novel corona virus, SARS-CoV-2, appeared in December 2019 in Wuhan, China, spreading much faster than its predecessors and the virus has already infected millions of patients worldwide as of April 19, 2020. As the scope of the current COVID-19 outbreak has reached proportion of pandemics, major international efforts in public health are underway to control the outbreak. However, as definitive treatments for confirmed COVID-19 are yet to be identified, there is considerable interest in repeating existing antiviral drugs for use against COVID-19.

Favipiravir triphosphate is a purine nucleoside analogue. This acts as a competitive inhibitor of RNA-dependent RNA polymerase. It has activities against influenza A and B, including oseltamivir- and zanamivir-resistant influenza viruses, several antimicrobial antiviral drugs, such as SARS-CoV-2. Favipiravir is approved for influenza strains that do not respond to standard antiviral therapy in Japan.

IMPACT ON PRICE

A large number of challenges are being faced by various market players due to the coming of the novel coronavirus, one such issue is the uncertainty surrounding the impact of covid-19 on favipiravir demands. Due to the increased demand of favipiravir for coronavirus treatment and stiff competition between the market players the rice of favipiravir has decreased.

According to the data available even as physicians share the benefits of Favipiravir for mild to moderate COVID-19 patients, a number of general launches are anticipated to intensify the price war that has already begun., Last month, Glenmark Pharma has receive a regulatory approval for Favipravir which has lowered its tablet price to Rs 75 each from Rs 103 earlier, anticipating market competition. 8 other favipiravir brands are at least expected to be launched in the upcoming days. At a price of Rs 59 per tablet, the Hetero Pharma became the third company to launch its generic version of Favipiravir, called Favivir. Previously, Mumbai-based Jenburkt Pharma put the low cost brand to date, Favivent, at Rs 39 per tablet. The company has started stockpiling in Mumbai and aims to expand its share of Maharashtra before it expires nationwide.    

With the increasing demand and increasing sale of favipiravir drugs, the competition between the favipiravir drugs manufacturers has increased market, leads to the fall of favipiravir drugs price.

IMPACT ON DEMAND

The Corona virus zone is the result of various markets around the world. This is the cause of the widespread closures and isolation that are affecting world economic activity.

In Japan Favipiravir which is an oral antiviral drug approved for the treatment of influenza. It specifically inhibits RNA polymer, which is necessary to copy the virus. Japan has begun a Phase 3 clinical trial. In the United States, a phase 2 study will involve approximately 50 patients with COVID-19, in collaboration with Brigham and the Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School. In India, a Phase 3 trial began combining two antiviral drugs, favipiravir and umifenovir, in May 2020.    

Chemists and pharmacists are in the high demand for the antiviral drug Favipiravir, which was launched under the brand name "fabi-influenza" by Glenmark drugs. It has been approved for limited emergency use in for the COVID-19 patients with mild to moderate symptoms by (ICMR) Indian Council of Medical Research.

The impact of COVID-19 has created an opportunity for the number of patients as there are high chances of adverse health effects of COVID-19 on the people.    

IMPACT ON SUPPLY

As the epidemic intensifies, supply chains can be at significant risk due to over-located locations that can potentially be disrupted. The supply chain of drugs has been disrupted. The spread of COVID-19 makes it difficult for governments to use these drugs; the availability of these systems faces constant challenges due to their components of use as well as limited initial needs.

Lasa Supergenerics already has export orders from abroad. The drug is sought after in Turkey, Jordan, Spain, and Portugal and so on where it is used in COVID-19 patients. Exports have no restrictions as they are based on our own specifications and not under the name of specific pharmacology.

This is an opportunity to confirm that India is indeed the 'Pharmacology of the World'.  As the world seems to be using reusable drugs to control COVID-19 until an effective and safe vaccine is developed, India has played a key role in providing some key drugs such as hydroxychloroquine (HCQ) and favipiravir for humanitarian and commercial purposes.

The trade restrictions have chosen nothing more than to produce the necessary medicines domestically. During the pandemic, when the demand increases, counterfeiting and price increases of imported goods increase. This signifies that even during the COVID-19 pandemic the market players are able to maintain supply chain.

STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS

As the coronavirus continues to spread to various countries, concerns are growing about disruptions in drug production and distribution. Collaborations, agreements, initiatives of market participants such as Fujifilm Corporation in the pharmaceutical market have helped them to expand their market. This in turn will help to increase the demand for the product among the consumers and thus increase the future sales of the company.

Market players have already taken different initiatives to combat the corona virus.

For instance,

·         In July 2020, Hyderabad's Hetero group announced that the generic drug Favipiravir would be introduced in India under the brand name "Favilavir" for the treatment of mild to moderate COVID-19. Hetero obtained approval from the Indian Anti-Doping Agency (DCGI) to manufacture and market the generic drug.

·         In July 2020, Cipla Limited announced that it has received the approval of the Indian anti-doping agency (DCGI) to place favipiravir in the country under the Ciplenza brand. Early approval for the manufacture and marketing of the drug aims to meet the urgent and undeveloped medical need for COVID-19 treatment options in the country with limited emergency use. It has been developed jointly by Cipla and the CSIR (Council of Scientific and Industrial Research) - Indian Institute of Chemical Technology (IICT). As part of this partnership, CSIR-IICT has successfully developed a convenient and cost-effective process for Favipiravir. The whole process and the active ingredient (API) of the medicine have been transferred to Cipla to manufacture and market the medicine in magnitude.

·         In July 2020, The Indian pharmaceutical company giant Dr. Reddy's Laboratories (Dr Reddy's) has signed a tripartite agreement with Fujifilm Toyama Chemical and Dubai Response Global Aid (Dubai) for the development, production and sale of the favipiravir innovation brand Avigan. Under the terms of the agreement, it is assumed that FUJIFILM will receive a license fee and commissions for sales from Dr. Reddy and GRA. Dr Reddy has exclusive rights to manufacture Avigan, while both GRA and Dr Reddy have joint the rights to develop, sell the market the drug worldwide except Japan, China and Russia. 

·         In June 2017, In India, Glenmark Pharmaceuticals has started in Phase III clinical trials of the drug. The results of the Glenmark study, which records up to 150 patients, will be available in July or August 2020.

·         In April 2017, Fujifilm Corporation (Tokyo, Japan) has initiated a clinical trial in II. Stage study to evaluate the safety and efficacy of the influenza antiviral drug Avigan tablet (synonymous with favipiravir) in patients with COVID-19, a respiratory tract infection caused by the novel SARS-CoV-2 coronary heart virus. Avigan was the first antiviral drug approved for use in the treatment of COVID-19 in China. At the beginning of March, when production in Avigan began, the company was producing approximately 40,000 treatment courses per month. The company plans to gradually increase this to up to 100,000 treatment courses per month by the end of July (approximately 2.5 times more). The overall goal, according to FUJIFILM, is to accelerate the production of up to 300,000 treatment courses per month by September 2020.

With the increasing demand and increasing sale of favipiravir drugs, are fueling the growth of favipiravir drugs market in the near future. As such, market participants are involved in the production of favipiravir drugs expanding their business through a variety of programs, including collaboration, contracts, and pipeline development, collaboration, and market expansion. It is expected that the strategic decisions of these companies will provide significant opportunities for market participants operating in the favipiravir market. 

CONCLUSION

The available clinical evidence suggests that favipiravir is relatively safe for total cell carcinoma, as well as serious gastrointestinal side effects. However, an increase in the blood uric acid is still a safety issue, as shown in a pooled analysis of larger studies, with evidence of increased dose-dependent development. Further safety concerns, such as the possibility of Corrected QT Interval (QTc) malformation and prolongation, have not yet been adequately investigated.

There is an evidence to support the safety and tolerability of favipiravir during short-term treatment. However, more evidence is needed to assess the effects of long-term treatment. Given the limitations of the evidence and the specific safety concerns that remain, the widespread use of favipiravir against pandemic COVID-19 should be justified. Various manufacturers have allowed their manufacturers to remotely operate the production of favipiravir at various production sites in safe areas around the world and help them maintain a stable supply chain. In addition, increased demand for favipiravir for the treatment of coronavirus has increased profits.

[techsciresearch]

India Dexamethasone Market to Witness Significant Growth During Forecast Period – TechSci Research

Increasing number of cases and deaths caused due to COVID-19 is expected to drive the growth of India dexamethasone market

According to TechSci Research report, “India Dexamethasone Market By Type (Injectables, Capsules, Tablets, Solutions), By Route of Administration (Oral v/s Intravenous), By Application (Asthma, Rheumatoid Arthritis, Skin Disorders, Covid-19, Ulcerative Colitis, Lupus, Allergic Disorders, Psoriasis, Others), By End Users (Hospitals, Clinics, Pharmacy, Others), By Region, Forecast & Opportunities, FY2026”, the India dexamethasone market is expected to grow at an impressive rate during the forecast period on account of the use for treating various diseases such as arthritis, skin conditions, eye care, respiratory & breathing problems, among others. Additionally, dexamethasone is a corticosteroid hormone which decreases body’s own defensive response and reduces symptoms such as swelling, allergic reactions, among others. This is an off-patent drug which is sold as a generic drug and also under the brand name DexPak, which is cost effective and manufactured by various big and small pharmaceutical companies in the country. Furthermore, the use of drug in high risk patients of COVID-19 is further expected to spur the market growth. However, side effects such as irritability, insomnia, muscle weakness, fluid retention, mood swings, increased appetite, increased blood sugar level, among others might hamper the market growth through FY2026. Also, cytokine over storm while fighting the deadly coronavirus might further restrict the market growth over the next few years.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on " India Dexamethasone Market"

https://www.techsciresearch.com/report/india-dexamethasone-market/4935.html

The India dexamethasone market is segmented based on type, route of administration, application, end users, company and region. Based on type, the market can be categorized into injectables, capsules, tablets, and solutions. Here, the tablets segment is expected to dominate the market since they are safe, inexpensive, and safest form of oral medication. Additionally, they have a long shelf life, durable, chewable and can be split. Also, they can accommodate high dose of active ingredient. On the other hand, the capsule segment is expected to witness significant growth in the market since these are tasteless, tamper resistant and break down faster and easily. Further, they have a higher bioavailability and make a large amount of drug enter the bloodstream. Based on route of administration, the market can be split into oral and intravenous. Among these, the oral route is expected to dominate the market on account of its ease, safety, self-administration, prolonged absorption, among others. Additionally, the ease of digestion, efficient patient compliance and ability to accommodate various types of drugs further drive the segmental growth.

Cadila Healthcare Ltd., Wockhardt Ltd., Dwarkesh Pharmaceuticals Private Limited, Schwitz Biotech, Lexine Technochem Private Limited, Mapro Lifescience, Therawin Formulations, Shervotec Pharmaceuticals, Acichem Laboratories, Quality Nexgen Pharmaceuticals Pvt Ltd and others are some of the leading players operating in India dexamethasone market.

Download Sample Report  @ https://www.techsciresearch.com/sample-report.aspx?cid=4935

Customers can also request for 10% free customization on this report.

“India dexamethasone market is expected to grow at a formidable rate during the forecast period on account of the emergence of the drug as a potential option to treat chronic COVID-19 patients and increasing the survival rate. India has a large number of pharmaceutical companies that are producing the drug at a very affordable rate. However, an increase in the price of API is expected by the drug manufacturers since more than 75% of the API are exported from China but due to the current border tensions with China and also halt in trading activities might lead to an increase in the manufacturing costs during the forecast period. Moreover, the drug has brought a ray of hope to the world for preventing deaths due to COVID-19 and if it gets the approval from FDA it will create lucrative opportunities for the market growth. Also, it will be quite beneficial for Indian pharmaceutical industry since India is one among the major producers of the drug.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“India Dexamethasone Market By Type (Injectables, Capsules, Tablets, Solutions), By Route of Administration (Oral v/s Intravenous), By Application (Asthma, Rheumatoid Arthritis, Skin Disorders, Covid-19, Ulcerative Colitis, Lupus, Allergic Disorders, Psoriasis, Others), By End Users (Hospitals, Clinics, Pharmacy, Others), By Region, Forecast & Opportunities, FY2026”,has evaluated the future growth potential of India dexamethasone market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India dexamethasone market.

Browse Related Reports

Global Hydroxychloroquine and Chloroquine Market By Type (Injectables & Tablets), By Route of Administration (Oral v/s Intravenous), By Strength (100mg, 250mg & 500mg), By Application (Rheumatoid Arthritis, Malaria, COVID-19, Others), By Region, Competition, Forecast & Opportunities, 2030

https://www.techsciresearch.com/report/chloroquine-and-hydroxychloroquine-market/4609.html

Asia Pacific Favipiravir Market By Route of Administration (Oral v/s Intravenous), By Dosage Form (Tablet v/s Capsule), By Distribution Channel (Hospitals, Clinics, Drug Stores/Pharmacies, Online, Others), By Application (Influenza A&B, Ebola, COVID-19), By Country, Forecast & Opportunities, 2025

https://www.techsciresearch.com/report/asia-pacific-favipiravir-market/4719.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-165

Email: sales@techsciresearch.com

[theinnernetsurfer]

#2.3 – What can we do? What is the government doing?

Hi! I hope you’ve read #2, #2.1 and #2.2 before getting here. If not, please click on their links.😊

—

As with most things in life, the coronavirus too shall pass.

But from what we've seen in the last three months, it's set to stay longer than we all initially anticipated. Till a vaccine comes around, our focus should be on how we can position ourselves, to not only survive this period, but also come out stronger on the other side?

First, we must realise that though the lockdowns have ended, the threat to human life remains. History tells us that - the Spanish Flu of 1918 was most devastating in its second wave. And there could very well be a second wave of the coronavirus in India. So let's continue to be cautious, wear masks, exercise social distancing and maintain a high level of hygiene.

Second, since the economy has slowed down, and it looks like we're going to be in a recession for the next 2-4 years, we must invest in ourselves. Improve our skills and build new ones. One could use this time to improve one's health, mind-space, digital expertise, and so on.

Three key lessons ring through for individuals and organisations alike -

Be more conscious of how your actions affect Mother Nature.

Debt is a double edged sword. If you have any, pay it off as soon as possible.

Invest in digital.

While science and healthcare have do the heavy lifting of saving lives, policymakers must shoulder the burden by saving livelihoods and incomes.

Let's look at what the chief commander - the Reserve Bank of India (RBI) and the captain of the ship - the Government of India (GOI) have been doing to steer the ship to safety.

Reserve Bank of India

The RBI’s job is to regulate the flow of money in the economy, with the goal of controlling inflation. How does it do this? Well, the RBI regulates all the banks and NBFCs. And those two, put together, effect the flow of most of the liquidity in the system.

The RBI has taken a number of steps to free up liquidity and add more of it, to keep the economic time machine ticking. The rationale is - when businesses find themselves in a hole, they need extra liquidity for some time to dig their way out. By making liquidity available to the banks, the RBI has encouraged them to lend, and this should revive the economy ie. bring back the flow of money!

Yes, there could be some damage, like, rise in inflation (since more money is available but activity levels are still low), and some defaults by borrowers who are unable to dig their way out of this situation. But the other alternative is the death of many, many businesses.

Here is a simplified version of steps taken by RBI -

For the banks -

Banks are required to keep a certain percentage of its deposits with the RBI and an additional percentage with themselves, as a safety measure to meet withdrawal requests. These percentages have been reduced by the RBI. This frees up money for lending.

Lent money to banks at attractive rates. This additional money was to be used to purchase corporate bonds, commercial papers and non-convertible debentures. This would ease redemption pressures being faced by companies borrowing through bonds.

Guided banks to put in place disaster recovery and business continuity plans. Example - alternative data sites, etc.

Allowed banks to participate in offshore currency markets. This allows banks to hedge their risks.

Reduced compliance and regulatory burden on banks.

Added funds to NABARD (National Bank for Agriculture and Rural Development), SIDBI (Small Industries Development Bank of India) and NHB (National Housing Bank). These provide long term funding to agriculture and rural sectors, small industries, housing finance companies, NBFCs and micro-finance institutions.

The RBI is the banker for the Central Government and State Governments. States are allowed to borrow up to certain limits only. These limits have been increased and terms of borrowing have been relaxed.

Other measures -

Eased compliances on exports.

Offered a liquidity facility to mutual funds, to support them during mass redemption pressure during this time.

For the benefit of all borrowers - offered moratorium period on loans taken from all financial institutions, and then extended the period due to continued stress.

Government of India

The GOI is similar to a team of whole time directors who run a massive company called India. They’re tasked with a wide range of functions. From an economic policy standpoint however, the GOIs job is to achieve the economic growth target in an inclusive manner, and reduce unemployment. How is this done? By supporting the business and entrepreneurial environment in the country through - development projects, tax and regulatory policies, fair and approachable departments, attracting foreign investment, access to finance, and so on.

The GOI has taken the following steps to save lives and livelihoods, and to reposition India as a stronger economy. It's an ambitious plan covering a multitude of topics, and execution will be key.

For economically backward classes - Direct benefit transfers, free ration, free gas cylinders, special credit facility for street vendors, doubled cap of collateral free loans to women in self-help groups, loan relief.

Financial support to - senior citizens, widows, specially abled, women jan-dhan account holders.

For migrant labour - shelters created for urban homeless providing three meals a day + essentials (face masks and hand sanitisers), free food grains, MGNREGA support to returning migrants, etc.

For frontline workers - free - medical insurance with ₹50 lakh cover, masks, hydroxychloroquine tablets, PPEs.

For farmers - direct benefit transfers, distribution of many more kisan credit cards, and agri loans with moratorium benefit announced.

Total overhaul of the agriculture supply chain planned through a new central act (coming soon). Through cluster based approaches micro enterprises will be formalised. Schemes for transportation and storage of all fruits and vegetables announced. These reforms will allow farmers to access a wider market and get better prices for their produce, and should attract participation from the private sector, agri entrepreneurs and startups.

For MSMEs (Micro, Small and Medium Enterprises) measures like - collateral free loans, equity infusion, TDS relaxations, eased compliance, provident fund contribution. Disallowing global participation in tenders up to ₹250 Crores. Liquidity support to lenders.

For formal economy workers - health and safety code made applicable, annual health check-up and appointment letters made mandatory.

Tech driven online education - Radio and podcasts to be used. 3 channels launched, 12 in pipeline. Support for visually and hearing impaired students. Health and emotional well being support for students, families and teachers launched. Top 100 universities to be permitted to start online courses.

Reforms focused on the ease of doing business announced - empowered group of secretaries appointed to fast-track clearances, project development cells within each ministry to be set up, states to be ranked on investment attractiveness to promote healthy competition.

Sector specific initiatives announced in - power sector, battery storage, coal mining, minerals, defence, aviation, social infrastructure (roads, railways, public facilities, etc), space exploration. This should bring in more private participation and hence improve efficiency.

Some other initiatives -

Changed FDI policy to protect Indian companies from opportunistic acquisitions from abroad.

Infused liquidity into power distribution companies.

Schemes announced for converting government funded housing in cities into affordable rental complexes. And incentivising development of affordable rental housing.

Set up PM Cares fund - to combat the pandemic.

Set up a Rural Infrastructure Fund.

Afforestation initiatives launched to help restore ecological balance and provide jobs.

Provided financial support to dairy corporations and beekeeping initiatives.

Offered relief to fisheries industry.

Vaccination and tagging of animals done on a large scale.

Though I'm concerned about the spread of the pandemic, the ominous second wave, and the cruel impact COVID will have on our country's fiscal deficit (amount by which government spending exceeds government revenue) - I genuinely feel optimistic about the prospect of India coming out stronger on the other side of this financial crisis.

[pharmaphorumuk]

What COVID-19 means for generics companies

Generics companies have found themselves at the forefront of fighting COVID-19 – but it has required rapid change at all levels of the business. We spoke to Accord’s executive vice president EMENA, Dr James Burt, to get an on-the-ground view of how drug firms like his have had to adapt in these unpredictable times.

How has the COVID-19 pandemic affected generics companies like yourselves? 

Everyone has had to adapt, that much is clear – but more than adapt, we had to pre-empt how the situation would unfold, as far as we could.

We, and other manufacturers like us, have had to plan very carefully to ensure that our medicines continue to reach patients in a range of apocalyptic-like scenarios.

Take the UK for example; Accord currently supplies approximately one in five generic medicines to the NHS. That is a serious responsibility for us and security of supply is critical.

In early February, it was clear that we were about to experience a global pandemic. We had already developed our own forecasting model to predict which medicines would be in demand and when; which in turn has enabled us to ship active pharmaceutical ingredients (API) before export bans and, at the same time, step up our production to match the surge in requirements across the EU.

“One challenge will be to take the learnings from this pandemic and make sure we are never in the same position again in terms of drug shortages”

I recognise my bias here, but I have been completely bowled over by the dedication of our staff in the most challenging conditions continuing to manufacture and deliver supplies of vital medicines where they have been needed most. Production lines, batch sizes and delivery volumes have had to be rapidly changed to meet growing demand and ensure sufficient stocks of a range of medicines are available in the EU. We have likened it to war times within Accord; imagining future generations asking how we played our part in the efforts against COVID-19. I hope we are justified in saying that we are incredibly proud of our contribution.

How have you tried to ensure business continuity?

Continuity is king when it comes to medicine supply. Logistics turned out to be a key COVID-19 challenge. As passenger flights were cancelled it became immediately apparent that much of the world’s pharmaceutical supply is carried as ‘belly cargo’ in commercial flights and, overnight, available air cargo was reduced to almost zero. On top of this, with lockdown came extreme issues with border and customs controls.

We worked with a number of groups such as BGMA, Medicines for Europe and the Indian Pharmaceutical Association to lobby governments to introduce practical measures such as ‘green lane-ing’, classification of pharmaceutical staff as key workers exempted from quarantining and returning customs, logistics and other necessary staff to ensure the flow of medicines. We also worked hard with airlines and export companies to return access to freight.

Are there any specific drugs or initiatives you are focusing on at the moment?

Our scientific team scoured the medical literature looking for older medicines that could be repurposed. The anti-inflammatory, anti-malarial, hydroxychloroquine, was identified very early-on as a candidate for clinical research. We proactively shipped the active pharmaceutical ingredient from Asia before the export bans hit and within 22 days, we had successfully manufactured approved (within its existing MA) hydroxychloroquine here in the EU. We were proud to donate this initial supply of two million tablets to the world’s biggest interventional COVID-19 study, involving 40,000 frontline healthcare workers.

Last month the Department for Health and Social Care announced that the UK’s supplies of vital muscle relaxant medicines for patients using mechanical ventilators would be exhausted in just a few days. Given our focus on increasing our ICU medicines production, as soon as we understood the scale of the pandemic, we increased our supply in anticipation of this surge in demand.

It’s not just the lesser known medicines that the generics industry is relied on for – paracetamol has been in significantly greater demand during this pandemic. Anticipating this, we also increased production of paracetamol and have worked with governments and regulatory bodies to ensure patients have access to it when needed.

How can different stakeholders work together to tackle the crisis?

That’s the question that we were asking from the very beginning. No single company can – or should be trying to – provide the solution to this exceptional global emergency alone. Our industry is highly competitive, but there is simply no room for players trying to ‘out-do’ their competitors during this crisis.

We spent a lot of time lobbying for healthcare companies to work together as never before, to help identify and resolve gaps in essential medicines supply, in order to ensure the EU had access to vital COVID-19 medicines and to avoid over-ordering or stockpiling.

One great example was that we were approached by another pharmaceutical company that was looking to significantly expand its production to meet the surge demand from intensive care units. This company was able to make more of some vital pain relief products but didn’t have enough controlled drug storage space. We happen to operate the largest manufacturer-owned storage and distribution centre in the UK and so we were happy to offer that capacity to them to assist in increasing supplies to hospitals.

If an effective treatment is found, how can the industry ensure maximum possible patient access to it?

Again, collaboration is essential. If we return to the example of hydroxychloroquine, with the world running out of the raw ingredients to manufacture this COVID-19 investigational drug, Accord took the unprecedented step of partnering with another UK company, Sterling Pharma Services, to purchase and ship the raw materials required to produce hydroxychloroquine API in the UK. This means we have secured a domestic European supply that will help meet predicted European demand and ensure we are not reliant on imports, thereby helping ensure patient access.

Are there any other challenges in this environment that you foresee affecting you in the future?

One challenge will be to take the learnings from this pandemic and make sure that we are never in the same position again in terms of the drug shortages that healthcare systems have been facing across Europe.

Generic medicines have been viewed as a commodity like anything else; clothing, cars, computers, which is why so much of Europe’s supply chain is outsourced to Asia. Where purchase decisions are purely based on price, not value, the players in the market respond by driving efficiency savings via offshoring and gaining economies of scale. The corollary of this is massive aggregation of supply into a few very large, potentially fragile, supply chains. The situation reduces resilience, effectively putting all eggs in one basket.

From an industry-perspective, companies need to think about what their value proposition is at home and abroad. Governments will also need to look at this. We need to lobby to ensure procurement of medicine is not necessarily just focused on delivering the absolute lowest price, but also giving some weight to other attributes such as how diversified and resilient supply chains are, what the carbon footprint is like and safety or utility advantages. Within European public procurement, the concept of Most Economically Advantageous Tendering is already on the statute book, it just needs to be applied more wisely in the future.

About the interviewee

Dr James Burt has over 20 years plus experience in the pharmaceutical industry, predominantly in the generics and biosimilar sector. He joined Accord in 2010 and now leads the company’s operations in the EMENA territory, with particular responsibility for developing and delivering the company’s strategy to improve access to high quality affordable medicine within the region.

The post What COVID-19 means for generics companies appeared first on .

from https://pharmaphorum.com/views-analysis-market-access/what-covid-19-means-for-generics-companies/

[nrlobo50]

India exports 50 million hydroxychloroquine tablets to U.S. for COVID-19 fight: source

[khabrisala]

India exports 50 million hydroxychloroquine tablets to U.S. for COVID-19 fight: source

India exports 50 million hydroxychloroquine tablets to U.S. for COVID-19 fight: source

© Reuters. Researchers set up new labs to help fight coronavirus at the University of Minnesota

By Neha Arora and Sumit Khanna

NEW DELHI/AHMEDABAD (Reuters) – India has shipped 50 million tablets of hydroxychloroquine to the United States, an Indian source with direct knowledge of the exports said, although U.S. regulators warned the anti-malarial drug may have harmful side…

[news4me]

India Sends 5.5 Million Hydroxychloroquine Tablets to UAE to Combat Coronavirus

[ad_1]

India had put a ban on exports as sales soared to secure supplies for itself as US President Donald Trump touted the drug as a potential treatment for the coronavirus. Reuters

Updated:April 19, 2020, 12:03 PM IST

Representative image. Dubai:India has agreed to send hydroxychloroquine tablets to the United Arab Emirates to be used for treating COVID-19 patients, the…

[bigyack-com]

India dials up medical diplomacy, sends 85 mn HCQ tablets to 108 countries - india news

India has dialled up its medical diplomacy, sending loads of medicines to 100-plus countries over the last two weeks to help them fight the Covid-19 pandemic. A top government official told Hindustan Times that India is supplying nearly 85 million hydroxychloroquine tablets and close to 500 million paracetamol tablets to the 108 countries.This is apart from the 1,000 tonnes of paracetamol granules that have been sent to make tablets.“As we speak, a total of 4,000 plus consignments to 60 countries are being cleared for dispatch,” the government official cited above said. In all, the medicine supplies will cover 108 countries.Many of the supplies have been made through special Indian Air Force flights, foreign evacuation charters and even diplomatic cargo.It is a huge exercise, and complicated too given that most countries, including India, have shut flight operations. As one example, officials speak about how Indian HCQ tablets to be delivered to the Dominican Republic, which is the current President of the UNSC, were placed as diplomatic cargo on a US evacuation flight to Atlanta, Georgia. This diplomatic cargo will then be flown from New York to the island in the Carribean region in a Dominican charter later on Thursday. The HCQ tablets sent as gifts to Mauritius and Seychelles were loaded on special Indian Air Force planes on Wednesday for delivery. For reaching the medicines to Afghanistan, efforts are being made to send the medicine by a special charter.According to South Block officials, 5 million HCQ tablets and a large quantity of paracetamol has been either supplied or in the process of being supplied to 31 countries as grant assistance to combat Covid-19.“The emphasis has been on clearing consignments to those friendly countries first which are badly affected by the virus. We will also be clearing requests from some other countries who have sought help in this hour of need. This will be done in a day or two,” said a senior official.Basically, India has decided to supply all the drugs that were lying in special economic zones or 100 percent export oriented units after ensuring that there was an adequate buffer stock for domestic requirements in a worst-case scenario.“Broadly, almost everything that was ready and lying at the airports/ports that cannot be used domestically as on April 14 has been cleared for exports,” said a Ministry of External Affairs official.India has already supplied 80 million HCQ tablets to 24 countries through commercial contracts including US, UK, Russia, France, Spain and Netherlands. It has also supplied large quantities of paracetamol to 52 countries including Italy, Sweden and Singapore. In some cases, both HCQ and paracetamol tablets were supplied. Read the full article